Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIM HIGH: Adjuvant Interferon Alfa-2a in High-Risk Melanoma
NCT00002892Phase 3Completed
- Sponsor
- The Institute of Cancer Research
- Start
- Oct 1995
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of interferon alfa-2a in Malignant Melanoma (MM), sponsored by The Institute of Cancer Research. Started Oct 1995; status: completed.
02
Drugs
interferon alfa-2a
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00002892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002892.